ACE inhibitor- Versus angiotensin II blocker-induced cough and angioedema

Annals of Pharmacotherapy

Volumn 32, Issue 10, 1998, Pages 1060-1066

  Pylypchuk, George B ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Angioedema; Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Cough

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; COUGHING; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; COUGH; HUMANS; LOSARTAN; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0031765704     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17388     Document Type: Review

References (63)

1. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
2. Yeo WW, Ramsay LE. Persistent dry cough with enalapril: incidence depends on method used. J Hum Hypertens 1990;4:517-20.
3. Herman RJ, Pylypchuk GB, Evans BL. Prevalence and incidence of cough in patients on treatment with angiotensin converting enzyme inhibitors (abstract). Clin Pharmacol Ther 1996;59:139.
4. Kiesman MA, Evans B, Semchuk WM. Etiology and treatment of angiotensin converting enzyme inhibitor-induced cough. Can J Hosp Pharm 1995;48:25-31.
5. Efstratopoulos AD, Meikopoulos M, Voyaki S. Frequency of cough during therapy with ACE inhibitors in Greek hypertensives. J Hum Hypertens 1993;7:607-9.
6. Strocchi E, Valtancoli G, Ricci C, Malini PL, Bassein L, Ambrosioni E. Postmarketing studies of subjective side effects; a case for strict methodological criteria and careful analysis of data. Pharmacol Res 1992;25 (suppl 1):79-80.
7. Ogihara T, Mikami H, Katahira K, Otsuka A. Comparative study of the effects of three angiotensin converting enzyme inhibitors on the cough reflex. Am J Hypertens 1991;4(suppl):46S-51S.
8. Punzi HA. Safety update: focus on cough. Am J Cardiol 1993;72:45H-8H.
9. Yesil S, Yesil M, Bayata S, Postaci N. ACE inhibitors and cough. Angiology 1994;45:805-8.
10. Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 1996;60:582-8.
11. Kubota K, Kubota N, Pearce GL, Inman WHW. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in prescription-event monitoring. Eur J Clin Pharmacol 1996;49:431-7.
12. Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril-induced cough (letter). Lancet 1992;339:372.
13. Yeo WW, Foster G, Ramsay LE. Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine. Q J Med 1991;81:763-70.
14. Woo KS, Norris RM, Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995;75:967-8.
15. Herman RJ, Walker R, Pylypchuk GB, Khouri M, Evans BL. Angiotensin converting enzyme inhibitors (ACE-I) and cough, not all who cough have the ACE-I cough (abstract). Clin J Invest Med 1995;18: 1372.
16. Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nature Med 1996;2:814-7.
17. Tomaki M, Ichinose M, Miura M, Hirayama Y, Kageyama N, Yamauchi H, et al. Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P. Thorax 1996;51:199-201.
18. Thysell H, Andersson K-E, Andersson S-I, Ekman R. Angiotensin-converting enzyme inhibition, cough and the serum concentration of substance P. Eur J Clin Pharmacol 1988;34:649-50.
19. Hartung H-P, Heininger K, Schäfer B, Toyka KV. Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism. FASEB J 1988;2:48-51.
20. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf 1996;15:72-8.
21. Olsen CG. Delay of diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor-induced cough in office practice. Arch Fam Med 1995;4:525-8.
22. Simon SR, Black HR, Moser M, Berland WE. Cough and ACE inhibitors. Arch Intern Med 1992;152:1698-700.
23. Chung KF, Lalloo UG. Diagnosis and management of chronic persistent dry cough. Postgrad Med J 1996;72:594-8.
24. Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.
25. Fogari R, Zoppi A, Tettamanti F, Malamani GD, Tinelli C, Salvetti A. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992;19:670-3.
26. Charlon V, Dollow S, Fidel J, Hoglund C, Honkanen T, Kobrin I, et al. Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study. Br J Clin Pharmacol 1995;39: 125-9.
27. Germino FW, Lastra J, Pool P, Punzi H, Spinowitz B, Smith W, et al. Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor associated cough - a pilot study. Curr Ther Res 1993;54:469-75.
28. Sharif MN, Evans BL, Pylypchuk GB. Cough induced by quinapril with resolution after changing to fosinopril. Ann Pharmacother 1994;28:720-2.
29. Malini PL, Strocchi E, Zanardi M, Milani M, Ambrosioni E. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet 1997;350:15-8.
30. Timmermans PBMWM, Wong CM, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
31. Product information. Cozaar (losartan potassium tablets). West Point, PA: Merck, 1997.
32. Package insert. Avapro (irbesartan tablets). Princeton, NJ: Bristol-Myers Squibb, 1998.
33. Prescribing information. Diovan (valsartan capsules). East Hanover, NJ: Novartis Pharmaceuticals, 1997.
34. Ogihara T, Arakawa K, Iimura O, Abe K, Saruta T, Ishii M, et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV-116. J Hypertens 1994;12(suppl 9):S35-8.
35. Ogihara T, Nagano M, Mikami H, Higaki J, Kohara K, Azuma J, et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994;16:74-86.
36. Larochelle P, Flack JM, Hannah S, Smith S, Hwa J, Reeves RA. Irbesartan versus enalapril in severe hypertension (abstract). Am J Hypertens 1997;10(pt 2):131A.
37. Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, Osbakken M. Comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of hypertension (abstract). J Hypertens 1997;15(suppl 4):S117.
38. Tikkanen I, Omvik P, Jensen HÆ. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-51.
39. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995;17:911-23.
40. Ruff D, Gazdick LP, Berman R, Goldberg AI, Sweet CS. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996;14: 263-70.
41. Ramsay LE, Yeo WW. ACE inhibitors, angiotensin II antagonists and cough. J Hum Hypertens 1995;9(suppl 5):S51-4.
42. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147-51.
43. Grün A, Francillon A, Bodin F, Heath R, Muller M, Boutelant S, et al. A comparison of the efficacy and tolerability of a new angiotensin II antagonist, valsartan, with enalapril in patients with mild-to-moderate essential hypertension (abstract). Eur Heart J 1995;16(suppl):61.
44. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension - efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9.
45. Benz J, Oshrain C, Henry D, Avery C, Chiang Y-T, Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-7.
46. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-5.
47. Yasky J, Angela M, Grandin L, Godoy J. The beneficial effect of losartan on angiotensin-converting enzyme inhibitors (ACE) cough (abstract). Am J Hypertens 1996;9(pt 2):166A.
48. Donati-Genet P, Bianchetti MG. Modulators of the renin-angiotensin-aldosterone system and cough in childhood. Pediatr Nephrol 1996;10: 545-6.
49. Austin KF. Disorders of immune-mediated therapy. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:1630-8.
50. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WHW, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988;260:967-70.
51. Pillans PI, Coulter DM, Black P. Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1996;51: 123-6.
52. Hedner T, Samuelsson O, Lunde H, Lindholm L, Andrén L, Wilholm BE. Angiooedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992;304:941-6.
53. Thompson T, Frable MA. Drug-induced, life-threatening angioedema revisited. Laryngoscope 1993;103(pt 1):10-2.
54. Brown NJ, Nadeau JH. Does race predispose to angiotensin-associated angioneurotic edema (letter)? Ann Intern Med 1993;119:1224.
55. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996;60:8-13.
56. Jain M, Armstrong L, Hall J. Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy. Chest 1992;102:871-4.
57. Brunet P, Jaber K, Berland Y, Baz M. Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors. Am J Kidney Dis 1992; 19:444-7.
58. Gregory KWP, Davis RC. Angioedema of the intestine. N Engl J Med 1996;334:1641.
59. Diehl KL, Wernze H. Angioneurotic oedema caused by angiotensin converting enzyme inhibitors. Dtsch Med Wochenschr 1992;117:727-32.
60. Boxer M. Accupril-and Cozaar-induced angioedema in the same patient (letter). J Allergy Clin Immunol 1996;98:471.
61. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan (letter). N Engl J Med 1995;333:1572.
62. Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997;90:552-3.
63. Anderson MW, deShazo RD. Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J Allergy Clin Immunol 1990;85:856-8.